

Dosimetric Comparison of 3-dimensional Conformal Technique, Intensity-modulated, Volumetric Arc Modulation, and Helical Tomotherapy with Radixact in Patients with Breast Cancer

💿 Serap YÜCEL, 1 💿 Damla POYRAZ, 2 💿 Erhan DİŞÇİ, 2 💿 Zeynep GÜRAL, 1 💿 Fulya AĞAOĞLU 1

¹Department of Radiation Oncology, Acıbadem Mehmet Ali Aydınlar University, Atakent Hospital, İstanbul-Türkiye ²Department of Health Physics, Medipol University, Institute of Health Sciences, İstanbul-*Türkiye*

OBJECTIVE

Adjuvant radiotherapy (RT) has been used often at breast cancer treatment. RT techniques differ from each other in terms of accessibility and applicability. We aimed to compare the dosimetric evaluations of four modern RT techniques through ten breast cancer patients that had been treated previously with intensity-modulated RT (IMRT) technique.

METHODS

A single-center dosimetric study was performed based on treatment plannings of left-sided breast cancer patients. The patient's images, simulated at computed tomography with deep inspiration breath hold technique between March and June 2023, were used. Four different techniques, field-in-field (FinF), dynamic IMRT (dIMRT), volumetric modulated arc treatment (VMAT), and helical therapy (HT) were created on each patient image. Conformal index (CI) and homogeneity index (HI) were calculated. Mean doses of heart, contralateral breast, volume of doses 5 Grey (Gy) (V5) and 10 Gy (V10) of left lung and to-tal lungs were also calculated for each plan and the descripted and comparisons analysis was performed.

RESULTS

The better results of CI and HI were reported with dIMRT, VMAT, and HT techniques. However, these approaches were expected with increased percentage of lower doses at organs at risk (OAR). The lowest of V5 of left and total lungs, mean heart, and contralateral breast doses were achieved with FinF techniques, HT values were observed similar to FinF by these factors at OAR. Particularly, the lowest V20 value was demonstrated at HT techniques.

CONCLUSION

Adjuvant RT techniques at breast cancer still carry controversial subtitles. New technologic improvements might be indispensable and treatment plannings should be based on the individual properties of patients.

Keywords: Breast cancer; helical tomotherapy; intensity-modulated; radiotherapy. Copyright © 2023, Turkish Society for Radiation Oncology

Received: August 22, 2023 Accepted: August 30, 2023 Online: September 09, 2023

Accessible online at: www.onkder.org

OPEN ACCESS This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



Dr. Serap YÜCEL Acıbadem Mehmet Ali Aydınlar Üniversitesi, Atakent Hastanesi, Radyasyon Onkolojisi Kliniği, İstanbul-Türkiye E-mail: serapbaskaya@yahoo.com

INTRODUCTION

Breast cancer is the most common malignant tumors among the women.[1] Adjuvant radiotherapy (RT) is one of the standard treatments in particular cases and decreases locoregional recurrence and disease-free survival.[2,3] Three-dimensional conformal radiotherapy (3D-CRT) is the most widely used method of treatment planning and delivery at breast cancer RT. With the improvements at RT planning systems and devices, more conformal treatment plans have been achieved and doses at organs at risk (OAR) have been avoided using intensity-modulated radiotherapy (IMRT). Deep inspiration breath hold (DIBH) technique is an essential modern improvement for IMRT to achieve lower mean heart doses and better protection of OAR.[4,5] In the current practice, RT plannings of left-sided breast cancer patients are performed with DIBH technique as long as the RT devices are eligible to do so.

In the era of dosimetric optimization, homogenous dose distribution and coverage at target volumes with decreased high doses at OAR have been obtained with these IMRT techniques.[6–11] Hence, similar local control rates and survivals were reported with a lower RT-related adverse effects.[12–16] Rotational IMRT has been developed more recently. Volumetric-modulated arc therapy (VMAT) or helical tomotherapy (HT) is the forms of rotational IMRT at RT departments. Better target volumes coverage and dose homogeneity have been observed not in all patients, but also at patients with complexity for RT planning.[17–21]

Although it is expected that new RT techniques would allow the increase of the efficacy/toxicity ratio, some unexpected dose distributions were encountered. The low doses could occur in any region inside treatment fields, even leading to higher OAR doses in some cases. Patient anatomy is an important determinant, so it would be the guide for the choice when comparing techniques.

This study aimed to present the results of comparison of RT techniques at left-sided breast cancer patients. Plans with field-in-field (FinF), dynamic-IMRT (dIMRT), VMAT, and HT were compared for each patient using the same planning contours to gather data about target and OAR.

MATERIALS AND METHODS

Data Selection

A single-institution, retrospective study was planned to analyze the comparison of treatment plans. Ten patients treated in the Department of Radiation Oncology between March 2023 and June 2023 were selected. The inclusion criteria were the early stage left-sided breast cancer, having breast-conserving surgery and no chemotherapy treatment. Patients allowed to receive hormonotherapy during RT. Median age of patients is 54.10 years (range 42–73). Patients with breast implants were excluded from the study.

Dosimetric Analysis

Patients were immobilized supine by C-Qual breast board (Civco Medical Instruments Co. Inc. Coralville, Iowa, USA) with the left arm above the patient's head. Real-time Position Management (RPM, Varian Medical Systems Inc., Palo Alto, USA) system was used for the breath-holding method. An RPM localizer box was placed on the skin between the chest and abdomen of the patients and was followed by the cameras. All cases were delineated by the same senior radiation oncologist based on the images obtained for each patient with a computed tomography (CT) simulator (Somatom Force, Siemens Healthiners, Germany).

The clinical target volume was consisted of breast tissue with the guidance of ESTRO and planning target volume (PTV) was created by adding 5 mm margins in all directions and cropped 3 mm under the skin. OAR was defined as heart, left lung, contralateral breast, and total lungs and delineated. Prescribed dose was 50 Gy in 25 fraction and optimization was based on the constraint that ensuring 95% isodose line encompasses 95% of PTV.

Eclipse planning system (version 13.6, Varian Medical Systems, Palo Alto, CA, USA) was used for FinF, dIMRT, and VMAT plans. HT plans were calculated at HT planning station (Radixact, Accuray Precision, version 3.3.1.2; Sunnyvale, CA, USA). The different treatment techniques have been applied to the patients' data set without any clinical application. This activity does not require an ethical approval according to our institution's rules.

The same criteria of biophysical dosimetric evaluation for each structure were used. Dose-volume histograms were calculated for each planning. The mean doses, D2 and D98 doses of PTV, were recorded. Conformal index (CI) and homogeneity index (HI) were calculated. CI was defined as the quality of target dose distribution, taking into account the dose inside versus outside the PTV and HI was obtained from the target D2, D50, and D98 doses.[22,23] The formulas were chosen in such a way that the optimal value for CI is 1 and for HI is 0. Mean doses of all OAR were recorded and other factors as values for the percentage of the left lung and total lungs that received 5 Gy (V5) and 20 Gy (V20) were obtained.

Table 1 PTV coverage comparison					
Variable (mean)	FinF	dIMRT	VMAT	нт	
н	0.1570	0.2140	0.0930	0.1220	
CI	0.9980	1.0570	0.9070	1.0650	

PTV: Planning target volume; FinF: Field-in-field; dlMRT: Dynamic-intensitymodulated radiotherapy; VMAT: Volumetric modulated arc treatment; HT: Helical therapy; HI: Homogeneity index; CI: Conformal index

Statistical Analysis

For descriptive statistics, mean±standard deviation was used to present continuous data with normal distribution. Median with minimum-maximum values was applied for continuous variables without normal distribution. Numbers and percentages were used for categorical variables. The Paired Samples t-test was used for comparison and analysis of the difference between any 2 of 4 plans. Data analysis and graphic presentations were performed using the SPSS program, version 23.0 (SPSS Inc.).

RESULTS

Average values of HI, CI, and mean doses OAR with four different treatment plannings were summarized at Tables 1 and 2. While Table 3 presents the comparison between each plan and allows the significance, Table 4 shows the indices comparison of quality of plans with HI and CI values.

On two main quality indices, there was better homogeneity for VMAT compared to FinF, but the comparison of HI between others showed no significance. All plannings were created with the aim for the good homogeneity. Greater conformity for all intensitymodulated techniques was reported compared to FinF. Thus, CI 95% was improved in both dIMRT, VMAT, and HT highly significantly, but non-significant difference between dIMRT and HT was observed.

For the dose to the heart, lower mean doses were achieved with the plans with FinF and HT techniques, significantly. The highest mean heart doses were observed with VMAT plans. HT plans showed the lowest V20 both to the left lung and total lung. Furthermore, FinF and dIMRT plans reported lower total lung V20 doses, but the left lung V20 doses were significantly lowest with HT plans. The lowest V5 doses to the left lung, total lung, and contralateral breast were observed with FinF plans as expected. On the other hand, HT plans showed no significant difference from FinF for left lung V5 doses and significant lower left lung V5 doses from dIMRT and VMAT plans.

Table 2 OAR sparing and statistic values						
Variable (mean)	FinF	dIMRT	VMAT	нт		
Heart D _{Mean} (Gy)	2.6390	4.2480	6.57	2.28		
L Lung V20 (%)	25.00	23.40	44.50	11.710		
L Lung V5 (%)	44.00	53.60	81.50	48.75		
T Lung V20 (%)	12.2740	12.2390	20.700	10.620		
T Lung V5 (%)	19.9280	23.00	54.00	37.75		
Contralateral	0.7070	0.8830	2.6840	2.3180		
breast D _{Mean} (Gy)						

OAR: Organs at risk; FinF: Field-in-field; dIMRT: Dynamic-intensity-modulated radiotherapy; VMAT: Volumetric modulated arc treatment; HT: Helical therapy; L: Left; T: Total

DISCUSSION

The use of RT for breast cancer has become widespread due to the high number of patients. For achieving optimal results, modern RT techniques are being used and have advantages from traditional RT techniques. However, some caveats to these advances were known and treatment planning has to be created individually for each patient. The knowledge of benefits of these modern RT techniques can help to determine preferences at planning process.

The milestone of modern RT technique was IMRT that has been used common at RT departments since 2000s. Afterward, arc treatments have been taken a great part with the time and provided dose coverage advantages at many cancer type. The results of this trial indicated the comparison of these current modern methods with FinF plannings, based on 3D-CRT technique, and each other at left-sided breast cancer simulated with DIBH technique.

In the left-sided breast irradiation, the aim is to minimize the dose to the heart to decrease any late cardiac toxicity.[24] Many techniques have been tried to achieve this low heart mean dose at RT departments, and today each center has its own preferred technique.[11,17,19] Respiratory control is one the most preferred and DIBH is easily adapted by patients. Not only the advantage of eliminating movement of respiratory for IMRT techniques, but also the advantage of increasing distances between target and OAR is concluded with DIBH. All the plans were created on images obtained with DIBH technique during CT simulation. Hence, both the anatomical regions were ensured to be the same and the effect of the advantage on each planning technique was observed.

Regarding dose conformity and homogeneity, there is a clear theoretical advantage for IMRT, VMAT, and HT

Table 3 FinF vs dIMRT vs VMAT vs HT at OAR comparison

Heart D _{men} (Gy) FinF AdMMT -1.60 -3.93 -2.26 -0.95 -0.37.1.92 0.000 S S AHT 0.35 -0.37.1.09 0.297 NS AMRT 0.35 -0.37.1.09 0.003 S AMT 1.96 0.86-3.06 0.003 S AMT 1.96 0.86-3.06 0.003 S MAT 1.96 0.86-3.06 0.003 S AMT 1.96 0.86-3.06 0.003 S MMAT -19.50 -2.898-0.13.02 0.000 S AMT 1.12.9 4.88-17.69 0.000 S AMT 1.12.9 4.96-40.61 0.000 S AMT -9.60 -15.28 - 0.91 0.004 S AVMAT -37.50 -45.26 - 29.73 0.000 S AMT -37.50 -45.26 - 29.73 0.000 S AMT -37.50 -37.73 - 18.66 0.000 S AMT -4.52 -10.102 0.102	OAR	Parameters	Estimate	CI 95%	р	S
Lung V20 (%) Lung	Heart D (Gy)	FinF				
AWMAT -3.93 -5.312.54 0.000 S. AMMT -0.35 -0.37-1.09 0.297 NS AWMT -2.32 -3.62 0.003 S WMAT 1.96 0.86-3.06 0.003 S WMAT 1.96 -2.83-6.03 0.436 NS AMT 1.29 -2.89-6.03 0.436 NS AWMAT -19.50 -2.898-1.30.2 0.000 S AWMAT -19.20 -2.898-1.30.2 0.000 S AWMAT -19.20 -2.895-1.3.24 0.000 S AWMAT -21.20 -2.895-1.7.32 0.000 S AMT 1.169 6.29-17.08 0.001 S AMT 32.79 2.496-40.61 0.000 S AMT -3.73 0.000 S AMT -4.52 0.973 0.000 S AMT -4.82 -1.9-1.1.60 0.000 S AMT -1.9.6 0.000 S </td <td>mean * **</td> <td>ΔdIMRT</td> <td>-1.60</td> <td>-2.260.95</td> <td>0.000</td> <td>S</td>	mean * **	ΔdIMRT	-1.60	-2.260.95	0.000	S
АНТ 0.35 -0.37-1.09 0.297 NS diMRT AVMAT -7.32 -3.62 -1.01 0.003 S AHT 1.96 0.86-3.06 0.003 S WAT - 2.88-5.68 0.000 S LLung V20 (%) FinF - - AddMRT 1.60 -2.283-6.03 0.436 NS AVMAT -19.50 -2.58 13.02 0.000 S AHT 13.29 8.88-17.69 0.000 S AHT 12.02 -2.895 -13.24 0.000 S AHT 12.09 -2.78.6 0.001 S A AUMAT -2.10 -2.89.5 0.000 S A AUMAT -3.75 24.96-40.61 0.000 S A AUMAT -3.75 -15.28 -0.91 0.004 S AUMAT -2.790 -7.77.3 -18.06 0.000 S AHT <		Δνματ	-3.93	-5.312.54	0.000	S
AVMAT -3.22 -3.62 -1.01 0.003 S AHT 1.96 0.86-3.06 0.003 S WMAT -2.32 -3.62 0.000 S Llung V20 (%) Finf -2.83 0.436 NS AVMAT -19.50 -2.538 -13.02 0.000 S AHT 13.29 2.88-17.69 0.000 S AHT 13.29 2.496-40.61 0.000 S MAT -37.50 -45.26 -29.73 0.000 S AHT -10.65-1.15 0.102 NS MAT -37.50 -45.26 -29.73 0.000 S AHT 1.275 21.86-43.63 0.000 S MAT -1.65		ΔHT	0.35	-0.37-1.09	0.297	NS
ΔVMAT -2.32 -3.621.01 0.003 S ΔHT 1.96 0.86-3.06 0.003 S L Lung V20 (%) Finf -		dIMRT				
АНТ 1.96 0.86-3.06 0.003 S AHT 4.28 2.88-5.68 0.000 S LLung V20 (%) AHT 1.60 -2.83-6.03 0.436 NS AVMAT -19.50 -2.83-6.13 0.400 S AVMAT -19.50 -2.83-7.13.02 0.000 S AHT 13.29 8.88-17.69 0.000 S AHT 11.69 6.29-17.08 0.001 S WMAT - 2.89.513.24 0.000 S WMAT - 2.89.513.24 0.000 S WMAT - - 0.001 S A WMAT - - 0.29.513.24 0.000 S MAT -3.73 -45.26 -29.73 0.000 S AVMAT -32.75 -21.86-43.63 0.000 S AMT 4.85 -1.9-11.60 0.142 NS MAT -6.87 -3.7318.06		ΔνΜΑΤ	-2.32	-3.621.01	0.003	S
L Lung V20 (%) AHT 4.28 2.88-5.68 0.000 S ΔilMRT 1.60 -2.83-6.03 0.436 NS ΔilMRT -19.50 -25.9813.02 0.000 S ΔilMRT -19.50 -25.9813.02 0.000 S diMRT -21.20 -28.9513.24 0.000 S diMRT -21.20 -28.9513.24 0.000 S diMRT -21.20 -24.96 - 0.91 0.004 S diMRT -0.60 -15.28 - 0.91 0.004 S diMRT -37.50 -45.26 - 2.97.3 0.000 S diMRT -4.75 -10.65 - 1.15 0.102 NS diMRT -27.90 -37.73 - 18.06 0.000 S diMRT 0.03 -2.00-2.07 0.970 NS diMRT 0.03 -2.00-2.07 0.970 NS diMRT 0.03 -2.00-2.07 0.970 NS diMT 1.65 -8.15-11.46		ΔHT	1.96	0.86-3.06	0.003	S
ΔΗΤ 4.28 2.88-5.68 0.000 S ΔdIMRT 1.60 -2.83-6.03 0.436 NS ΔMAT -19.50 -25.9813.02 0.000 S ΔHT 13.29 8.88-17.69 0.000 S ΔMRT -21.20 -28.9513.24 0.000 S ΔHT 32.79 24.96-40.61 0.000 S ΔHT 32.79 24.96-40.61 0.000 S ΔHT -37.50 -45.2629.73 0.000 S ΔHT -37.50 -45.2629.73 0.000 S ΔHT -37.50 -10.65 -1.15 0.102 NS ΔHT -4.85 -1.9-11.60 0.014 NS ΔHT 4.85 -1.9-11.60 0.102 NS ΔHT 32.75 21.86-43.63 0.000 S ΔHT 1.61 -8.70-1.97 0.731 NS ΔHT 1.61 -8.70-1.94 0.731 NS		VMAT				
L Lung V20 (%) FinF Δ/WAAT -19.50 2.836.03 0.436 NS Δ/WAAT -19.50 2.5.98 13.02 0.000 S Δ/WAAT -2.12.0 -2.8.95 13.24 0.000 S Δ/WAAT -2.12.0 -2.8.95 13.24 0.000 S Δ/HT 11.69 6.29-17.08 0.000 S VMAT -2.12.0 -2.8.9513.24 0.000 S VMAT -2.7.9 24.96-40.61 0.000 S MIT -9.60 -15.280.91 0.000 S Δ/WAT -37.50 -45.262.97.3 0.000 S Δ/WAT -27.90 -37.7318.06 0.000 S Δ/WAT -27.90 -13.16 0.012 NS Δ/WAT -27.90 -13.73 0.003 S Δ/HT 1.65 -1.80-4.363 0.000 S Δ/WAT -8.42 -1.40-4.45 0.001 S Δ/HT		ΔHT	4.28	2.88-5.68	0.000	S
AdiMRT 1.60 -2.83-6.03 0.456 NS AHT 13.29 8.88-17.69 0.000 S AHT 13.29 8.88-17.69 0.000 S AHT 11.69 6.29-17.08 0.000 S WMAT -21.20 -28.9513.24 0.000 S WMAT -37.50 -6.29-77.08 0.000 S WMAT -37.50 -45.260.91 0.004 S AMT -37.50 -45.2629.73 0.000 S AMT -4.75 -10.65-1.15 0.102 NS AMAT -37.50 -37.73 - 18.06 0.000 S AHT 4.85 -1.9-11.60 0.142 NS VMAT -8.42 -12.40 - 4.45 0.001 S AHT 1.61 -8.15-11.46 0.712 NS MMAT -1.64 -13.173.75 0.033 S AHT 1.61 -8.70-11.94 0.731 NS <tr< td=""><td>L Lung V20 (%)</td><td>FinF</td><td></td><td></td><td></td><td></td></tr<>	L Lung V20 (%)	FinF				
Δ/МАТ -19.50 -25.98 -7.3.02 0.000 S Δ/МАТ -13.29 8.88-17.69 0.000 S Δ/МАТ -21.20 -28.95 -13.24 0.000 S Δ/Η 11.69 6.29-17.08 0.000 S V/MAT - - 8.95 3.27 0.000 S LLung V5 (%) FinF - - 0.004 S Δ/ΜΑΤ -37.50 -45.26 -29.73 0.000 S Δ/ΜΑΤ -37.50 -45.26 -29.73 0.000 S Δ/ΜΑΤ -47.5 -10.65<-1.15		ΔdIMRT	1.60	-2.83-6.03	0.436	NS
ΔΗΠ 13.29 8.88–17.69 0.000 S ΔVMAT -21.20 -28.9513.24 0.000 S ΔHT 11.69 6.29–17.08 0.001 S VMAT - 6.29–17.08 0.000 S UMAT 32.79 24.96–40.61 0.000 S LLung V5 (%) FinF 0.014 S Δ/MAT -37.50 -45.2629.73 0.000 S Δ/MAT -37.50 -45.2629.73 0.000 S Δ/MAT -47.5 -10.65-1.15 0.102 NS Δ/MAT -27.90 -37.7318.06 0.000 S Δ/HT 4.85 -1.9-11.60 0.142 NS VMAT -4.45 -1.9-11.60 0.142 NS VMAT -4.66 -13.173.75 0.003 S ΔHT 1.61 -8.15-11.46 0.712 NS ΔHT 1.61 -8.20-4.47 0.000 S ΔHT		Δνματ	-19.50	-25.9813.02	0.000	S
diMRT -21.20 -28.95 -13.24 0.000 S DHT 11.69 6.29-17.08 0.001 S VMAT		ΔHT	13.29	8.88–17.69	0.000	S
ΔVMAT -21.20 -28.95 -13.24 0.000 S AHT 11.69 6.29 1.7.08 0.001 S LLung V5 (%) FinF		dIMRT				
АНТ 11.69 6.29-17.08 0.001 S ИМАТ 32.79 24.96-40.61 0.000 S AIMT -9.60 -15.28 - 0.91 0.004 S AMMAT -37.50 -45.26 - 29.73 0.000 S AHT -4.75 -10.65 - 1.15 0.102 NS MIMAT -4.85 -1.9 - 11.60 0.142 NS MAT 32.75 21.86 - 43.63 0.000 S AUMAT -6.42 -12.404.45 0.001 S MAT 1.61 -8.15 - 11.46 0.712 NS MAT 1.61 -8.70 - 1.94 0.73 N		Δνματ	-21.20	-28.9513.24	0.000	S
L Lung V5 (%) AHT 32.79 24.96-40.61 0.000 S AdIMRT -9.60 -15.280.91 0.004 S AVMAT -37.50 -45.2629.73 0.000 S AVMAT -47.5 -10.65-1.15 0.102 NS dIMRT -47.5 -10.65-1.15 0.102 NS AUMAT -27.90 -37.7318.06 0.000 S AUMAT -27.90 -37.7318.06 0.000 S AHT 32.75 21.86-43.63 0.000 S AHT 32.75 21.86-43.63 0.000 S AHT 1.65 -12.40 -4.45 0.011 S AUMAT -8.42 -12.40 -4.45 0.001 S AHT 1.65 -8.15-11.46 0.712 NS AUMAT -8.46 -13.17 -3.07 NS AUMAT -16.1 -2.79.98 0.64 NS AUMAT -3.07 -6.6		ΔHT	11.69	6.29–17.08	0.001	S
ΔΗΤ 32.79 24.96-40.61 0.000 S LLung V5 (%) FinF ΔdIMRT -9.60 -15.280.91 0.004 S ΔWMAT -37.50 -45.2629.73 0.000 S ΔHT -4.75 -10.65-1.15 0.102 NS dIMRT -27.90 -37.7318.06 0.000 S ΔHT 32.75 21.86-43.63 0.000 S ΔHT 32.75 21.86-43.63 0.000 S T Lung V20 (%) FinF - - 0.970 NS ΔVMAT -8.42 -12.404.45 0.001 S ΔHT 1.65 -8.15-11.46 0.712 NS ΔVMAT -8.46 -13.173.75 0.003 S ΔHT 1.08 -0.72-0.88 0.64 NS FinF - - - - NS ΔHT 1.61 -8.70-11.94 0.731 NS ΔHT 1.61 -8.70		VMAT				
L Lung V5 (%) FinF AddIMRT -9.60 -15.28 -0.91 0.004 S AVMAT -37.50 -45.26 -29.73 0.000 S AHT -4.75 -10.65-1.15 0.102 NS dIMRT AVMAT -27.90 -37.7318.06 0.000 S AHT 4.85 -1.9-11.60 0.142 NS VMAT T Lung V20 (%) FinF T Lung V20 (%) FinF AddIMRT 0.03 -2.00-2.07 0.970 NS AVMAT -8.42 -12.404.45 0.001 S AHT 1.65 -8.15-11.46 0.712 NS AHT 1.65 -8.15-11.46 0.712 NS AHT 1.61 -8.70-11.94 0.731 NS AUMAT -34.07 -6.83-0.69 0.098 NS AHT -17.82 -72.59 -8.05 0.003 S AHT -17.82 -72.59 -8.00 S AHT -17.82 -72.59 -8.00 S AHT -17.82 -72.59 -8.00 S AHT -17.82 -72.59 -8.00 S AHT -1.61 -2.14 -1.68 0.000 S AHT -1.61 -2.14 -1.08 0.000 S AHT -		ΔHT	32.79	24.96-40.61	0.000	S
AdilMRT -9.60 -15.280.91 0.004 S AVMAT -37.50 -45.2629.73 0.000 S AHT -4.75 -10.65-1.15 0.102 NS dIMRT -27.90 -37.7318.06 0.000 S AHT 4.85 -1.9-11.60 0.142 NS VMAT -27.90 -37.7318.06 0.000 S T Lung V20 (%) HT 32.75 21.86-43.63 0.000 S AHT 1.65 -1.9-11.60 0.142 NS VMAT -9.60 -1.2.40 -0.70 0.970 NS AdIMAT -0.63 -2.00-2.07 0.970 NS AMMAT -8.42 -12.40 -4.45 0.001 S AHT 1.65 -8.15-11.46 0.712 NS MMAT -8.46 -13.173.75 0.003 S AHT 1.010 -0.72-20.88 0.64 NS MAT -3.07 <	L Lung V5 (%)	FinF				
Δ/MAT -37.50 -45.26 -29.73 0.000 S ΔHT -4.75 -10.65 1.15 0.102 NS dIMRT -27.90 -37.73 -18.06 0.000 S ΔHT 4.85 -1.9-11.60 0.142 NS VMAT -37.57 21.86-43.63 0.000 S T Lung V20 (%) FinF 0.01 S MAT -20.02.07 0.970 NS Δ/MAT -8.42 -12.40 4.45 0.001 S MAT 1.61 -8.15-11.46 0.712 NS Δ/MAT -8.46 -13.17 -3.75 0.003 S AHT 1.61 -8.70-11.94 0.731 NS MAT 1.61 -8.70-11.94 0.731 NS VMAT AHT 1.08 -0.72-20.88 0.64 NS Lung V5 (%) FinF JAHT 1.028 -0.72-50.88 0.64 NS AltT 1.028 -0.72-50.88 <		ΔdIMRT	-9.60	-15.280.91	0.004	S
АНТ -4.75 -10.65-1.15 0.102 NS dIMRT -27.90 -37.7318.06 0.000 S АНТ 4.85 -1.9-11.60 0.142 NS VMAT -27.90 -37.7318.06 0.000 S TLung V20 (%) FinF -11.40 0.142 NS AUMAT -8.42 -2.00-2.07 0.970 NS AVMAT -8.42 -12.404.45 0.001 S AHT 1.65 -8.15-11.46 0.712 NS MMAT -8.46 -13.173.75 0.003 S AHT 1.61 -8.70-11.94 0.731 NS VMAT -4.07 -6.83 -0.69 0.098 NS AHT 1.61 -8.70-11.94 0.731 NS VMAT -3.07 -6.83 -0.69 0.098 NS AHT 1.61 -8.70-1.194 0.731 NS VMAT -3.07 -6.83 -0.69 0.098 NS <td></td> <td>Δνματ</td> <td>-37.50</td> <td>-45.2629.73</td> <td>0.000</td> <td>S</td>		Δνματ	-37.50	-45.2629.73	0.000	S
dIMRT -27.90 -37.7318.06 0.000 S AHT 4.85 -1.9-11.60 0.142 NS VMAT 32.75 21.86-43.63 0.000 S T Lung V20 (%) Finf - - 0.0142 NS AdIINRT 0.03 -2.00-2.07 0.970 NS AVMAT -8.42 -12.40 - 4.45 0.001 S AHT 1.65 -81.51.1.46 0.712 NS dIMRT -0.03 -2.00-2.07 0.970 NS AUT 1.65 -81.51.1.46 0.712 NS dIMRT -1.61 -8.70-11.94 0.731 NS VMAT -8.46 -13.173.75 0.003 S AHT 1.0108 -0.72-20.88 0.64 NS VMAT -3.07 -6.83-0.69 0.998 NS AVMAT -3.07 -6.83-0.69 0.003 S dilmRT -17.82 -27.59 - 8.05 0.003 <		ΔHT	-4.75	-10.65-1.15	0.102	NS
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		dIMRT				
СНТ 4.85 -1.9-11.60 0.142 NS VWAT АНТ 32.75 21.86-43.63 0.000 S T Lung V20 (%) FinF 0.03 -2.00-2.07 0.970 NS ΔVMAT -8.42 -12.404.45 0.001 S S ΔHT 1.65 -8.15-11.46 0.712 NS ΔHT 1.61 -8.70-11.94 0.731 NS MAT 1.61 -8.70-11.94 0.731 NS VMAT -4.66 -0.72-20.88 0.64 NS T Lung V5 (%) FinF 0.014 NS AHT 1.018 -0.72-20.88 0.64 NS AHT -31.07 -6.83-0.69 0.098 NS ΔHMAT -31.07 -43.6624.47 0.000 S ΔHT -17.82 -27.598.05 0.003 S ΔHT -16.25 4.08-28.41 0.014 S Contralateral breast D _{Mean} (Gy) HT -1.62 </td <td></td> <td>Δνματ</td> <td>-27.90</td> <td>-37.7318.06</td> <td>0.000</td> <td>S</td>		Δνματ	-27.90	-37.7318.06	0.000	S
MAT 32.75 21.86-43.63 0.000 S T Lung V20 (%) FinF AdfMRT 0.03 2.00-2.07 0.970 NS AVMAT -8.42 -12.40 -4.45 0.001 S AHT 1.65 -8.15-11.46 0.712 NS dIMRT - -4.66 -13.17 -3.75 0.003 S AHT 1.61 -8.70-11.94 0.731 NS VMAT -8.46 -13.17 -3.75 0.003 S AHT 1.61 -8.70-11.94 0.731 NS VMAT -1.61 -8.70-11.94 NS AHT 10.08 -0.72-20.88 0.64 NS AUMAT -34.07 -43.66 -24.47 0.000 S AUMAT -31.00 -40.56 -21.43 0.000 S AUMAT -14.75 -24.91 -4.58 0.003 S AHT 16.25 4.08-28.41		ΔHT	4.85	-1.9-11.60	0.142	NS
ДНТ 32.75 21.86-43.63 0.000 S T Lung V20 (%) FinF		VMAT				-
T Lung V20 (%) FinF ΔdliMRT 0.03 -2.00-2.07 0.970 NS ΔWMAT -8.42 -12.404.45 0.001 S ΔHT 1.65 -8.15-11.46 0.712 NS dlMRT -8.46 -13.173.75 0.003 S ΔHT 1.61 -8.70-11.94 0.731 NS VMAT -4.46 -13.173.75 0.003 S VMAT 1.61 -8.70-11.94 0.731 NS VMAT 1.01 -8.70-11.94 0.731 NS VMAT -10.08 -0.72-20.88 0.64 NS MHT 10.08 -0.72-20.88 0.64 NS MMAT -34.07 -43.66 - 24.47 0.000 S AHT -17.82 -27.598.05 0.003 S dlMRT -14.75 -24.914.58 0.009 S VMAT -14.75 -24.914.58 0.000 S MHT 16.25		ΔHT	32.75	21.86-43.63	0.000	S
AdiMRT 0.03 -2.00-2.07 0.970 NS AVMAT -8.42 -12.404.45 0.001 S AHT 1.65 -8.15-11.46 0.712 NS dIMRT -8.46 -13.173.75 0.003 S AHT 1.61 -8.70-11.94 0.731 NS VMAT -8.46 -13.173.75 0.003 S AHT 1.61 -8.70-11.94 0.731 NS VMAT - -8.46 -0.72-20.88 0.64 NS T Lung V5 (%) FinF - - - NS AdMAT -3.07 -6.83-0.69 0.098 NS AUMAT -3.07 -43.6624.47 0.000 S AHT -17.82 -27.598.05 0.003 S dIMRT -14.75 -24.914.58 0.009 S MHT 16.25 4.08-28.41 0.014 S Contralateral breast D _{Mean} (Gy) FinF -1.61	T Lung V20 (%)	FinF				
ΔVMAT -8.42 -12.404.45 0.001 S ΔHT 1.65 -8.15-11.46 0.712 NS dIMRT - - - - - - - - - - - 1.61 0.712 NS ΔHT 1.61 -8.70-11.94 0.731 NS - MS VMAT -8.46 -0.72-20.88 0.64 NS - NS VMAT 10.08 -0.72-20.88 0.64 NS - NS VMAT -3.07 -6.83-0.69 0.098 NS - NS - NM NO00 S - - AHT - - - - - - - AHT -		ΔdIMRT	0.03	-2.00-2.07	0.970	NS
ΔHT 1.65 8.15-11.46 0.712 NS dIMRT		ΔνΜΑΤ	-8.42	-12.404.45	0.001	S
ΔVMAT 8.46 -13.173.75 0.003 S ΔHT 1.61 8.70-11.94 0.731 NS VMAT 10.08 -0.72-20.88 0.64 NS T Lung V5 (%) FinF		ΔΗΤ dIMRT	1.65	-8.15-11.46	0.712	NS
ΔHT 1.61 -8.70-11.94 0.731 NS VMAT ΔHT 10.08 -0.72-20.88 0.64 NS T Lung V5 (%) FinF - - - - - - - - NS ΔdIMRT -3.07 -6.83-0.69 0.098 NS - NS ΔVMAT -34.07 -43.6624.47 0.000 S - S ΔHT -17.82 -27.598.05 0.003 S S dIMRT -14.75 -24.914.58 0.009 S ΔHT 16.25 4.08-28.41 0.014 S VMAT -1.97 -2.551.40 0.000 S ΔHT -1.97 -2.551.40 0.000 S ΔHT -1.61 -2.141.08 0.000 S ΔHT -1.61 -2.301.30 0.000 S ΔHT -1.43 -1.79 - 1.07 0.000 S ΔHT -1.43<		Δνματ	-8.46	-13.173.75	0.003	S
VMAT ΔHT 10.08 -0.72-20.88 0.64 NS T Lung V5 (%) FinF -3.07 -6.83-0.69 0.098 NS ΔdIMRT -34.07 -43.6624.47 0.000 S ΔVMAT -34.07 -43.6624.47 0.000 S ΔVMAT -31.07 -40.5621.43 0.000 S dIMRT -14.75 -24.914.58 0.009 S VMAT -16.25 4.08-28.41 0.014 S Contralateral breast D _{Mean} (Gy) FinF -0.17 -0.47-0.12 0.214 NS ΔVMAT -1.97 -2.301.30 0.000 S MIT ΔHT -1.61 -2.141.08 0.000 S<		ΔHT	1.61	-8.70-11.94	0.731	NS
ΔHT 10.08 -0.72-20.88 0.64 NS FinF ΔdIMRT -3.07 -6.83-0.69 0.098 NS ΔVMAT -34.07 -43.6624.47 0.000 S ΔHT -7.82 -27.598.05 0.003 S dIMRT -31.00 -40.5621.43 0.000 S MAT -31.00 -40.5621.43 0.000 S MAT -14.75 -24.914.58 0.009 S VMAT -14.75 -24.914.58 0.009 S VMAT -16.25 4.08-28.41 0.014 S Contralateral breast D _{Mean} (Gy) FinF - - S ΔHT -0.17 -0.47-0.12 0.214 NS ΔVMAT -1.97 -2.551.40 0.000 S ΔHT -1.61 -2.141.08 0.000 S ΔHT -1.80 -2.301.30 0.000 S ΔHT -1.43 -1.791.07		VMAT				
T Lung V5 (%) FinF ΔdIMRT -3.07 -6.83-0.69 0.098 NS ΔVMAT -34.07 -43.66 - 24.47 0.000 S ΔHT -17.82 -27.59 - 8.05 0.003 S dIMRT - - -40.56 - 21.43 0.000 S ΔVMAT -31.00 -40.56 - 21.43 0.000 S ΔHT -14.75 -24.91 - 4.58 0.009 S VMAT -14.75 -24.91 - 4.58 0.000 S ΔHT 16.25 4.08-28.41 0.014 S Contralateral breast D _{Mean} (Gy) FinF - - S ΔVMAT -0.17 -0.47-0.12 0.214 NS ΔVMAT -1.97 -2.551.40 0.000 S ΔHT -1.61 -2.141.08 0.000 S ΔHT -1.43 -1.79 - 1.27 0.000 S ΔHT -1.43 -1.791.07 0.000 S ΔHT <td></td> <td>ΔHT</td> <td>10.08</td> <td>-0.72-20.88</td> <td>0.64</td> <td>NS</td>		ΔHT	10.08	-0.72-20.88	0.64	NS
ΔdiMRT -3.07 -6.83-0.69 0.098 NS ΔVMAT -34.07 -43.6624.47 0.000 S ΔHT -17.82 -27.598.05 0.003 S dIMRT -31.00 -40.5621.43 0.000 S ΔHT -17.75 -24.914.58 0.009 S ΔHT -14.75 -24.914.58 0.009 S VMAT -14.75 -24.914.58 0.009 S VMAT -16.25 4.08-28.41 0.014 S Contralateral breast D _{Mean} (Gy) FinF - - - - ΔdIMRT -0.17 -0.47-0.12 0.214 NS ΔVMAT -1.97 -2.551.40 0.000 S ΔHT -1.61 -2.141.08 0.000 S GIMRT ΔVMAT -1.80 -2.301.30 0.000 S ΔHT -1.43 -1.791.07 0.000 S ΔHT -1.43 -1.791.07 <td>T Lung V5 (%)</td> <td>FinF</td> <td></td> <td></td> <td></td> <td></td>	T Lung V5 (%)	FinF				
ΔVMAT -34.07 -43.6624.47 0.000 S ΔHT -17.82 -27.598.05 0.003 S dIMRT - -43.6621.43 0.000 S ΔVMAT -31.00 -40.5621.43 0.000 S ΔHT -14.75 -24.914.58 0.009 S VMAT -14.75 -24.914.58 0.009 S VMAT -16.25 4.08-28.41 0.014 S Contralateral breast D _{Mean} (Gy) FinF - - - ΔdIMRT -0.17 -0.47-0.12 0.214 NS ΔVMAT -1.97 -2.551.40 0.000 S ΔHT -1.61 -2.141.08 0.000 S dIMRT - - -2.301.30 0.000 S dIMRT -1.43 -1.791.07 0.000 S MHT -1.43 -1.791.07 0.000 S WMAT -1.43 -1.791.07	-	ΔdIMRT	-3.07	-6.83-0.69	0.098	NS
ΔHT -17.82 -27.598.05 0.003 S dIMRT ΔVMAT -31.00 -40.5621.43 0.000 S ΔHT -14.75 -24.914.58 0.009 S VMAT -14.75 -24.914.58 0.009 S VMAT -16.25 4.08-28.41 0.014 S Contralateral breast D _{Mean} (Gy) FinF - - - NS ΔVMAT -0.17 -0.47-0.12 0.214 NS ΔVMAT -1.97 -2.551.40 0.000 S ΔHT -1.61 -2.141.08 0.000 S dIMRT -1.61 -2.141.08 0.000 S dIMRT -1.80 -2.301.30 0.000 S dHT -1.43 -1.791.07 0.000 S WAT -1.43 -1.791.07 0.000 S MAT -0.36 -0.14-0.87 0.141 NS		ΔνΜΑΤ	-34.07	-43.6624.47	0.000	S
dIMRT ΔVMAT -31.00 -40.5621.43 0.000 S ΔHT -14.75 -24.914.58 0.009 S VMAT 16.25 4.08-28.41 0.014 S Contralateral breast D _{Mean} (Gy) FinF - - NS ΔdIMRT -0.17 -0.47-0.12 0.214 NS ΔVMAT -1.97 -2.551.40 0.000 S ΔHT -1.61 -2.141.08 0.000 S dIMRT -1.63 -2.301.30 0.000 S dIMRT -1.43 -1.791.07 0.000 S dIMRT -0.36 -0.14-0.87 0.141 NS		ΔHT	-17.82	-27.598.05	0.003	S
ΔVMAT -31.00 -40.5621.43 0.000 S ΔHT -14.75 -24.914.58 0.009 S VMAT ΔHT 16.25 4.08-28.41 0.014 S Contralateral breast D _{Mean} (Gy) FinF - - - - - - - - - NS ΔVMAT -0.17 -0.47-0.12 0.214 NS - NS - AVMAT - 1.97 -2.551.40 0.000 S - AHT -1.61 -2.141.08 0.000 S - AHT -<		dIMRT				
ΔΗΤ -14.75 -24.914.58 0.009 S VMAT ΔΗΤ 16.25 4.08-28.41 0.014 S Contralateral breast D _{Mean} (Gy) Fin F ΔdIMRT -0.17 -0.47-0.12 0.214 NS ΔVMAT -1.97 -2.551.40 0.000 S ΔHT -1.61 -2.141.08 0.000 S dIMRT -1.63 -2.301.30 0.000 S ΔHT -1.43 -1.791.07 0.000 S ΔHT -0.36 -0.14-0.87 0.141 NS		ΔνΜΑΤ	-31.00	-40.5621.43	0.000	S
VMAT ΔHT 16.25 4.08–28.41 0.014 S Contralateral breast D _{Mean} (Gy) FinF -0.17 -0.47–0.12 0.214 NS ΔdIMRT -0.17 -2.55–-1.40 0.000 S ΔHT -1.61 -2.14 – -1.08 0.000 S dIMRT -1.63 -2.30 – -1.30 0.000 S ΔHT -1.43 -1.79 – -1.07 0.000 S ΔHT -1.43 -1.79 – -1.07 0.000 S ΔHT 0.36 -0.14–0.87 0.141 NS		ΔHT	-14.75	-24.914.58	0.009	S
ΔΗΤ 16.25 4.08–28.41 0.014 S Contralateral breast D _{Mean} (Gy) FinF NS ΔdIMRT -0.17 -0.47–0.12 0.214 NS ΔVMAT -1.97 -2.55–-1.40 0.000 S ΔHT -1.61 -2.14 – -1.08 0.000 S dIMRT -1.80 -2.30 – -1.30 0.000 S ΔHT -1.43 -1.79 – -1.07 0.000 S WMAT -1.43 -1.79 – -1.07 0.000 S VMAT -0.36 -0.14–0.87 0.141 NS		VMAT				
Contralateral breast D _{Mean} (Gy) Fin F ΔdIMRT -0.17 -0.47-0.12 0.214 NS ΔVMAT -1.97 -2.551.40 0.000 S ΔHT -1.61 -2.141.08 0.000 S dIMRT -1.80 -2.301.30 0.000 S ΔHT -1.43 -1.791.07 0.000 S VMAT -0.36 -0.14-0.87 0.141 NS		ΔHT	16.25	4.08-28.41	0.014	S
ΔdIMRT -0.17 -0.47-0.12 0.214 NS ΔVMAT -1.97 -2.551.40 0.000 S ΔHT -1.61 -2.141.08 0.000 S dIMRT -1.80 -2.301.30 0.000 S ΔVMAT -1.43 -1.791.07 0.000 S ΔHT -0.36 -0.14-0.87 0.141 NS	Contralateral breast D _{Mean} (Gy)	FinF				
ΔVMAT -1.97 -2.551.40 0.000 S ΔHT -1.61 -2.141.08 0.000 S dIMRT - - - - S ΔVMAT -1.80 -2.301.30 0.000 S ΔHT -1.43 -1.791.07 0.000 S VMAT - - - - - S ΔHT 0.36 -0.14-0.87 0.141 NS		ΔdIMRT	-0.17	-0.47-0.12	0.214	NS
ΔΗΤ -1.61 -2.141.08 0.000 S dIMRT ΔVMAT -1.80 -2.301.30 0.000 S ΔΗΤ -1.43 -1.791.07 0.000 S VMAT -0.36 -0.14-0.87 0.141 NS		Δνματ	-1.97	-2.551.40	0.000	S
dIMRT ΔVMAT -1.80 -2.301.30 0.000 S ΔHT -1.43 -1.791.07 0.000 S VMAT ΔHT 0.36 -0.14-0.87 0.141 NS		ΔHT	-1.61	-2.141.08	0.000	S
ΔVMAT -1.80 -2.301.30 0.000 S ΔHT -1.43 -1.791.07 0.000 S VMAT ΔHT 0.36 -0.14-0.87 0.141 NS		dIMRT				
ΔΗΤ -1.43 -1.791.07 0.000 S VMAT ΔΗΤ 0.36 -0.14-0.87 0.141 NS		Δνματ	-1.80	-2.301.30	0.000	S
VMAT ΔHT 0.36 –0.14–0.87 0.141 NS		ΔHT	-1.43	-1.791.07	0.000	S
ΔHT 0.36 –0.14–0.87 0.141 NS		VMAT				
		ΔHT	0.36	-0.14-0.87	0.141	NS

Δ: Difference between the plans for the criterion; S: Statistically significative result; NS: Statistically non-significative result. FinF: Field-in-field; dIMRT: Dynamicintensity-modulated radiotherapy; VMAT: Volumetric modulated arc treatment; HT: Helical therapy; OAR: Organs at risk; CI: Conformal index; L: Left; T: Total

Table 4 FinF vs dIMRT vs VMAT vs HT for quality parameters					
Quality parameters	Parameters	Estimate	CI 95%	р	S
н	FinF				
	ΔdIMRT	-0.05	-0.26-0.14	0.546	NS
	ΔνΜΑΤ	0.06	0.05-0.07	0.000	S
	ΔHT	0.03	-0.00-0.07	0.081	NS
	dIMRT				
	ΔVMAT	0.12	-0.09-0.33	0.232	NS
	ΔHT	0.09	-0.12-0.30	0.359	NS
	VMAT				
	ΔHT	-0.02	-0.06-0.01	0.131	NS
CI 95%	FinF				
	∆dIMRT	-0.05	-0.100.01	0.020	S
	ΔVMAT	0.09	0.01-0.16	0.024	S
	ΔHT	-0.06	-0.100.02	0.004	S
	dIMRT				
	ΔνΜΑΤ	0.15	0.08-0.21	0.001	S
	ΔHT	-0.00	-0.04-0.03	0.674	NS
	VMAT				
	ΔΗΤ	-0.15	-0.20.10	0.000	S

Δ: Difference between the plans for the criterion; S: Statistically significative result; NS: Statistically non-significative result. FinF: Field-in-field; dlMRT: Dynamicintensity-modulated radiotherapy; VMAT: Volumetric modulated arc treatment; HT: Helical therapy; CI: Conformal index; HI: Homogeneity index

compared to 3D conformal techniques.[11,19,25–28] CI and HI are considered important indicators for irradiation plans quality and help to compare different irradiation plans. However, the effect of these parameters at clinically is inaccurately known. In the study, VMAT has been reported as better for dose homogeneity as expected, but the only significance was observed between VMAT and FinF techniques. CI was superior at HT treatments compared with 3DCRT and VMAT, but similar with dIMRT. Hence, FinF technique as having the least appropriately was concerned and HT was the confluence of results.

Modern techniques usually consist great number of beams to have better conformity and homogeneity often at the expense of increased low-dose exposure for the tissue surrounding the tumor. Increased percentage of low dose bath may result in a higher risk of second malignancies for long mean life expected patients. [29,30] Comparison of techniques is having importance in terms of both understanding the superior homogeneity and conformity and minimized lower doses at OAR and longer follow-ups will give us the result of this low dose irradiation with advanced RT techniques.

In the analysis, lower doses at OAR had been observed with FinF techniques as expected. However, also HT plans provided low percentages, even more than FinF plans at V20 values of lung. While HT was reported as only significantly lower V20 for the left lung, total lung V20 values were not significant between HT, FinF, and dIMRT plans. In regard to V5 values, HT was seemed to lose advantage and FinF plans were having lower V5 values for the left lung and total lungs, but only significant for total lung V5 value. The difference between FinF, dIMRT from HT, and VMAT has been observed particularly at the contralateral breast and contralateral lung, both receiving relatively low dose.

In left-sided breast cancer irradiation, heart is considered the most important OAR in terms of deterministic late effects and risk of subsequent ischemic events.[25,30,31] Significant lower dose for mean heart dose was observed with FinF and HT techniques compared to dIMRT and VMAT. Whereas the lowest mean heart dose would be expected with the FinF technique, HT also had similar mean heart doses. This may be a result of the new Radixact system, because of new property of Radixact planning system with definitive blockages descriptions. With appropriate definitions and limitations of OAR, more precise plans can be achieved at this rotational therapy device. Likewise, significant lowest mean doses of left lung V20, total lung V20, and left lung V5 were reported with HT. The left lung also had the new described advantage of this rotational treatment, but naturally, this was concluded with further spread of the low dose to surrounding organs. VMAT and HT techniques both had significantly higher V5 doses at contralateral breast and contralateral lung.

CONCLUSION

Comparison of four techniques at breast cancer radiotherapy and the different advantages of treatment plans were analyzed. As result, RT technique should be based on the individual properties of the patient. Anatomic complexities, age, disease factors, etc. are all that a radiation oncologist takes into to give a decision.

Peer-review: Externally peer-reviewed.

Conflict of Interest: All authors declared no conflict of interest.

Financial Support: None declared.

Authorship contributions: Concept – S.Y., D.P.; Design – S.Y.; Supervision – E.D., F.A.; Funding – F.A.; Materials – Z.G.; Data collection and/or processing – S.Y., D.P.; Data analysis and/or interpretation – S.Y.; Literature search – S.Y., D.P.; Writing – S.Y.; Critical review – F.A.

REFERENCES

- 1. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 2016;17(S3):43–6.
- McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al; EBCTCG (Early Breast Cancer Trialists' Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: metaanalysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383(9935):2127–35.
- Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378(9804):1707–16.
- 4. Remouchamps VM, Letts N, Vicini FA, Sharpe MB, Kestin LL, Chen PY, et al. Initial clinical experience with moderate deep-inspiration breath hold using an active breathing control device in the treatment of patients with left-sided breast cancer using external beam radiation therapy. Int J Radiat Oncol Biol Phys 2003;56(3):704–15.
- 5. Nissen HD, Appelt AL. Improved heart, lung and target dose with deep inspiration breath hold in a large clinical series of breast cancer patients. Radiother Oncol 2013;106(1):28–32.
- 6. Dogan N, Cuttino L, Lloyd R, Bump EA, Arthur DW. Optimized dose coverage of regional lymph nodes in

breast cancer: the role of intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007;68(4):1238– 50.

- Kestin LL, Sharpe MB, Frazier RC, Vicini FA, Yan D, Matter RC, et al. Intensity modulation to improve dose uniformity with tangential breast radiotherapy: initial clinical experience. Int J Radiat Oncol Biol Phys 2000;48(5):1559–68.
- Barnett GC, Wilkinson J, Moody AM, Wilson CB, Sharma R, Klager S, et al. A randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. Radiother Oncol 2009;92(1):34–41.
- 9. Richmond ND, Turner RN, Dawes PJ, Lambert GD, Lawrence GP. Evaluation of the dosimetric consequences of adding a single asymmetric or MLC shaped field to a tangential breast radiotherapy technique. Radiother Oncol 2003;67(2):165–70.
- 10. Donovan EM, Bleackley NJ, Evans PM, Reise SF, Yarnold JR. Dose-position and dose-volume histogram analysis of standard wedged and intensity modulated treatments in breast radiotherapy. Br J Radiol 2002;75(900):967–73.
- 11. Lauche O, Kirova YM, Fenoglietto P, Costa E, Lemanski C, Bourgier C, et al. Helical tomotherapy and volumetric modulated arc therapy: New therapeutic arms in the breast cancer radiotherapy. World J Radiol 2016;8(8):735–42.
- 12. Donovan E, Bleakley N, Denholm E, Evans P, Gothard L, Hanson J, et al; Breast Technology Group. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 2007;82(3):254–64.
- 13. Mukesh MB, Barnett GC, Wilkinson JS, Moody AM, Wilson C, Dorling L, et al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol 2013;31(36):4488–95.
- 14. Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008;26(13):2085–92.
- 15. Buwenge M, Cammelli S, Ammendolia I, Tolento G, Zamagni A, Arcelli A, et al. Intensity modulated radiation therapy for breast cancer: current perspectives. Breast Cancer (Dove Med Press) 2017;9:121–6.
- 16. Keller LM, Sopka DM, Li T, Klayton T, Li J, Anderson PR, et al. Five-year results of whole breast intensity modulated radiation therapy for the treatment of early stage breast cancer: the Fox Chase Cancer Center experience. Int J Radiat Oncol Biol Phys 2012;84(4):881–7.

- 17. Caudrelier JM, Morgan SC, Montgomery L, Lacelle M, Nyiri B, Macpherson M. Helical tomotherapy for locoregional irradiation including the internal mammary chain in left-sided breast cancer: dosimetric evaluation. Radiother Oncol 2009;90(1):99–105.
- Chira C, Kirova YM, Liem X, Campana F, Peurien D, Amessis M, et al. Helical tomotherapy for inoperable breast cancer: a new promising tool. Biomed Res Int 2013;2013:264306.
- 19. Goddu SM, Chaudhari S, Mamalui-Hunter M, Pechenaya OL, Pratt D, Mutic S, et al. Helical tomotherapy planning for left-sided breast cancer patients with positive lymph nodes: comparison to conventional multiport breast technique. Int J Radiat Oncol Biol Phys 2009;73(4):1243–51.
- 20. Lauche O, Kirova YM. Helical tomotherapy in breast cancer treatment. Breast Cancer Manag 2014;3:441– 49.
- 21. Popescu CC, Olivotto IA, Beckham WA, Ansbacher W, Zavgorodni S, Shaffer R, et al. Volumetric modulated arc therapy improves dosimetry and reduces treatment time compared to conventional intensity-modulated radiotherapy for locoregional radiotherapy of left-sided breast cancer and internal mammary nodes. Int J Radiat Oncol Biol Phys 2010;76(1):287–95.
- 22. van't Riet A, Mak AC, Moerland MA, Elders LH, van der Zee W. A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate. Int J Radiat Oncol Biol Phys 1997;37(3):731–6.
- 23. Hodapp N. The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT). Strahlenther Onkol 2012;188(1):97–9.
- 24. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al; American Heart Association Cardiovascular Disease in Women and Special Popu-

lations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation 2018;137(8):e30–e66.

- 25. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368(11):987–98.
- 26. Dumane VA, Bakst R, Green S. Dose to organs in the supraclavicular region when covering the Internal Mammary Nodes (IMNs) in breast cancer patients: A comparison of Volumetric Modulated Arc Therapy (VMAT) versus 3D and VMAT. PLoS One 2018;13(10):e0205770.
- 27. Yu PC, Wu CJ, Nien HH, Lui LT, Shaw S, Tsai YL. Tangent-based volumetric modulated arc therapy for advanced left breast cancer. Radiat Oncol 2018;13(1):236.
- 28. Osman SO, Hol S, Poortmans PM, Essers M. Volumetric modulated arc therapy and breath-hold in imageguided locoregional left-sided breast irradiation. Radiother Oncol 2014;112(1):17–22.
- 29. Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys 2007;68(2):359-63.
- 30. Sardaro A, Petruzzelli MF, D'Errico MP, Grimaldi L, Pili G, Portaluri M. Radiation-induced cardiac damage in early left breast cancer patients: risk factors, biological mechanisms, radiobiology, and dosimetric constraints. Radiother Oncol 2012;103(2):133–42.
- Mège A, Ziouèche A, Pourel N, Chauvet B. Radiationrelated heart toxicity. Cancer Radiother 2011;15(6-7):495–503.